We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.50 | -0.23% | 212.50 | 534,008 | 16:35:12 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 211.50 | 213.50 | 214.00 | 209.00 | 213.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Home Health Care Services | USD 23.75M | USD -50.35M | USD -0.1839 | -11.50 | 579.23M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:55:25 | O | 3,861 | 212.40 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/4/2024 | 07:00 | UK RNS | PureTech Health PLC Notice of Results |
| 16/4/2024 | 21:57 | ALNC |  EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling |
| 16/4/2024 | 12:00 | UK RNS | PureTech Health PLC PRTC LYT-100 Ph2b in IPF Enrolled; Results Q4 2024 |
| 11/4/2024 | 13:01 | ALNC | US FDA hands fast track to PureTech head and neck cancer treatment |
| 11/4/2024 | 12:00 | UK RNS | PureTech Health PLC FDA Grants PRTC's LYT-200 Fast Track Designation |
| 09/4/2024 | 11:33 | ALNC | PureTech Health CEO Zohar moves to head-up portfolio firm Seaport |
| 09/4/2024 | 07:00 | UK RNS | PureTech Health PLC PRTC Launches Seaport w/ $100M; Leadership Changes |
| 19/3/2024 | 11:16 | ALNC | PureTech shares jump on USD100 million tender offer proposal |
| 19/3/2024 | 07:00 | UK RNS | PureTech Health PLC $100M Tender Offer |
| 18/3/2024 | 13:32 | UK RNS | PureTech Health PLC $14B Acquisition of PRTC’s Karuna by BMS Completed |
Puretech Health (PRTC) Share Charts1 Year Puretech Health Chart |
|
1 Month Puretech Health Chart |
Intraday Puretech Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/4/2024 | 16:00 | PureTech Health - innovative healthcare | 1,988 |
| 22/7/2018 | 21:35 | PureTech Health (PRTC) One to Watch Monday | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:55:33 | 212.40 | 3,861 | 8,200.76 | O |
| 16:32:14 | 212.48 | 10 | 21.25 | O |
| 16:32:01 | 212.50 | 556 | 1,181.50 | O |
| 16:24:31 | 211.50 | 74,477 | 157,516.62 | O |
| 16:24:31 | 212.50 | 22,426 | 47,654.80 | O |
| Top Posts |
|---|
Posted at 24/4/2024 09:20 by Puretech Health Daily Update Puretech Health Plc is listed in the Home Health Care Services sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 213p.Puretech Health currently has 273,866,153 shares in issue. The market capitalisation of Puretech Health is £579,226,914. Puretech Health has a price to earnings ratio (PE ratio) of -11.50. This morning PRTC shares opened at 213p |
Posted at 22/4/2024 11:45 by linton5 Oxb starting to motor now I see prtc pulled up at the 1st 🐎 |
Posted at 22/3/2024 15:03 by linton5 Share price is exactly where it was 1year ago I take it not much has happened 🤔 |
Posted at 21/3/2024 10:33 by wassapper So please help me here. The tender offer will be at 250p per share (if it proceeds)?Current share price is 222p So if I buy more now (to add to my goodly amount), sometime in April/May, I'll be offered 250p a share for some of my shares by the company? Do I make an "instant" 28p per share or just for a proportion? If so why aren't more share being bought? What happends to the share price after the tender offer (all things being equal)? Does it drop like a typical ex-divi action? First time tender for me so quite confused. I am sure many of these questions will be asked again! Thanks! |
Posted at 19/3/2024 21:00 by colinblackbourn These resources enabled us to create an exciting crop of new medicines that position us to repeat and scale this type of outcome - and we have done so without diluting our shareholders in over six years. We are delighted to be able to purchase shares of PureTech at this valuation and to concurrently provide some liquidity to our shareholders and additional capital returns beyond the recently completed $50 million share buyback. Following this proposed tender offer, we are confident that our strong balance sheet will continue to support the development of our existing pipeline - as well as the next wave of innovative medicines. Looking forward, the board will continue to assess ongoing opportunities to improve shareholder returns." As noted on 8 February 2024, the Company recently completed a $50 million Share Buyback Program, which - together with the proposed Tender Offer - would constitute $150 million of capital returned to shareholders, which is approximately 21% of the Company's market capitalization as of 18 March 2024. The Board determined the amount of the Tender Offer after considering feedback from a number of shareholders, tax implications, and the continued support of the Company's existing and future Programs, including the recently announced Founded Entities. PureTech aims to maintain at least three year's cash runway, and the Board intends to evaluate its capital allocation policy regularly to assess opportunities for additional capital returns to shareholders, subject to the Company's operational needs. |
Posted at 19/3/2024 12:35 by fozzie The stock market is crazy. You often get companies doing a small placing at a 20% discount and the share price drops to the placing price almost straightaway even though it might only be 5% of share capital. |
Posted at 19/3/2024 12:30 by return_of_the_apeman As the share price gets closer to £2.50, more will be inclined not to tender, which may mean a special divi as indicatedLooking forward to publication of results at the end of April |
Posted at 16/3/2024 16:37 by colinblackbourn 27 September 2023PureTech Health plcPureTech Announces the Appointment of Robert Lyne as Chief Portfolio OfficerPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases , today announced the appointment of Robert Lyne as Chief Portfolio Officer. Robert brings a decade of experience in international life science deals and portfolio management, along with governance and executive team leadership experience. Robert is expected to join PureTech by early January 2024."We are excited to welcome Rob to our management team and pleased to add a dedicated presence representing our senior leadership team in the UK as we work to deliver impactful new treatments for patients," said Daphne Zohar, Founder and Chief Executive Officer of PureTech. "His extensive legal, operational and UK listed IP commercialization experience is complementary to PureTech's own hub-and-spoke business model. We are looking forward to working together closely as we realize the full potential of both our Wholly Owned Programs and Founded Entity stakes and royalties."Mr. Lyne joins PureTech from Arix Bioscience plc, a transatlantic venture capital company focused on investing in innovative biotechnology companies, where he served as General Counsel and Chief Operating Officer before being appointed Chief Executive Officer in April 2021. He began his career as a lawyer at international law firm Bird & Bird LLP in London before moving to Touchstone Innovations, a London listed biotech and technology investor, which was acquired in 2017. He has worked on over 80 venture capital financings in Europe and North America as well as multiple trade exits and IPOs. As an experienced UK plc executive, Mr. Lyne has broad experience formulating and implementing corporate strategy. Mr. Lyne has a BA from the University of Oxford and an LLB from Oxford Brookes University."I am delighted to be joining the management team at PureTech during such an exciting time in the Company's growth," said Mr. Lyne. "As pioneers of the hub-and-spoke model in the biotechnology sector, PureTech's approach is aligned with my own experience and ambitions. They are highly innovative in their approach to both science and business, which has led to the team delivering an impressive track record of developing new therapies with transformational potential. I look forward to working with the skilled team at PureTech and its outstanding network of advisors to further drive the Company forward." |
Posted at 16/3/2024 12:58 by colinblackbourn Karuna $14bn closing frees up cash from the big holders.Fidelity will have made several billion dollars for example.100pc owned Seaport and Gallop will be looking for investors ahead of eventual IPO..Remember Seaport is 'Karuna on Steroids'.both ultimate valuations in for free.I wonder what the share price will be by the final results at the end of April. |
Posted at 27/2/2024 07:15 by takeiteasy 27 February 2024PureTech Health plc PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan Japanese Product Now Under Review for Nationwide Marketing Approval PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. (Nasdaq: AKLI) announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili's AKL-T01 (marketed as EndeavorRx® in the United States), which has previously been authorized by the U.S. Food and Drug Administration (FDA) as the world's first prescription digital therapeutic for improving attentional functioning in pediatric ADHD patients aged 8 to 17. "We are pleased by this additional validation of Akili's EndeavorRx," said Eric Elenko, Ph.D., Chief Innovation Officer at PureTech. "This game-changing technology is now poised to address the needs of pediatric patients with ADHD in Japan if approved, and this exciting milestone is yet another example of PureTech's contribution to changing the lives of patients in need." Feb 2024 presentation says we own 14.6% of Akilii so not a bad shout for Akili up 125% (yes, one hundred and twenty five - no misprint!) on this news...dyor etc |
Posted at 23/2/2024 14:06 by takeiteasy I know folks are all loading up here - but given the note at the top of the page notes value in the share at 1.42 in 2016 - what on earth has happened in the interim etc etc..given what must have been a very tough 8 years to 2024 what is a realistic target price now that some might take profits at.We have such a crazy range of numbers up to about 10 quid which almost seems mad to suggest in the light of dreadful share price performance over such a long 8 year period.. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
